Clinical Trial Update: A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of CNTO1275 in patients with multiple sclerosis has completed, with results posted. The sponsor was Centocor, Inc., and the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• CNTO1275 (ustekinumab)

Snippet

Sponsor: Centocor, Inc. | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2009-12-02